KETAMINE'S EFFICIENCY IN THE TREATMENT OF CHRONIC PAIN WITH INFLAMMATORY COMPONENT: EXPLORING THE KYNURENIN PATHWAYS.

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2018
INTERVENTION: Trade Name: KETAMINE KETAMINE PANPHARMA (50mg/5mL), Solution injectable IV‐IM Pharmaceutical Form: Solution for injection/infusion Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intravenous use CONDITION: The population selected is a spinal cord injury population with central neuropathic pain at the lesional or sub‐lesion level, chronically (for more than three months) Adult, spinal cord injury (SCI), with or = to 6/10 during the week preceding the inclusion ‐ Medullary lesion, whatever the origin (traumatic, degenerative, tumoral, postoperative), responsible for paraplegia in a chronic state. ‐ Able to give informed consent, after clear, fair and appropriate information ‐ Having given their consent by a written consent signature. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 8
Epistemonikos ID: f9ff8dee7907f6a584746b024c110d1b9ab9911c
First added on: Aug 24, 2024